Institute of Botany, Technologies Company Jointly Establish Labs for Tobacco Harm Reduction

Source from:  cas.cn 05/12/2008

The Kunming Institute of Botany of China Academy of Sciences in southwest China's Yunnan Province and Dabaihui Technologies Co., Ltd. in south China's Shenzhen City have recently signed an agreement on joint establishment of laboratories for developing tobacco harm reduction technologies. Under the agreement, the Kunming Institute of Botany of China Academy of Sciences and Dabaihui Technologies Co., Ltd. will cooperate in the establishment in Kunming and Shenzhen Cities of joint laboratories for developing tobacco harm reduction technologies. After the signing of the agreement, representatives from the two sides held discussions and exchanged points of view and opinions on preparation for the establishment of the joint laboratories, formation of the relevant scientific-technological research taskforces, substantive contents of the bilateral research and development plans for a next stage and other specific matters. Signing the agreement on behalf of the Kunming Institute of Botany was Deputy Director Liu Jikai of the institute. Representatives from the relevant research and management departments of the institute attended the signing ceremony. It was reported that Dabaihui Technologies Co., Ltd. is a company mainly engaged in the research and development, application and generalization of biotechnologies for reducing the content of harmful substances in cigarettes. The company is in possession of the patented biotechnology for producing Shennong Liquid used for tobacco harm reduction, to which it fully owns the intellectual property rights, and created the Wuyeshen cigarette brand -- China's first brand of reduced-harm cigarettes produced with biotechnology. In 2006, the actual sales volume of Wuyeshen ranked the fourth among all the Grade One cigarette brands of China. The current cooperation between the Kunming Institute of Botany and Dabaihui Technologies Co., Ltd. in joint establishment of the laboratories for developing tobacco harm reduction technologies is reportedly intended to further promote the development of tobacco harm-reducing biotechnologies to a higher level on the basis of existing achievements in developing reduced-harm tobacco products, by giving full play to their respective advantages, through mutual complementarity of technologies and cooperation between the two powerful entities, and by jointly striving to reduce the content of harmful substances in cigarettes, in order to make contribution to taking care of the health of tobacco consumers. Enditem